3'',4''-Diacetylafzelin | 77307-50-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3'',4''-Diacetylafzelin
• 英文别名: [4-acetyloxy-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-5-hydroxy-2-methyloxan-3-yl] acetate
• CAS: 77307-50-7
• 化学式: C₂₅H₂₄O₁₂
• 分子量: 516.4
• InChiKey: SXOZSDJHGMAEGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  128-132°C
• 沸点：
  753.0±60.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮（少许）、甲醇（少许）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  178
• 氢给体数：
  4
• 氢受体数：
  12

安全信息

• 储存条件：
  -20℃

制备方法与用途

生物活性

SL 0101-1（SL0101）是从热带植物F. refracta中提取得到的山萘酚糖苷，是一种能穿透细胞、选择性的、可逆的、ATP竞争性的p90核糖体S6激酶(RSK)抑制剂，其IC50值为89 nM。SL 0101-1（SL0101）是选择性RSK1/2抑制剂，Ki值为1 μM。

靶点

• IC50: 89 nM (RSK)
• Ki: 1 μM (RSK1/2)

体外研究

SL 0101-1（SL0101）在人类乳腺癌细胞系MCF-7中表现出增殖抑制作用，并产生G₁期的细胞周期阻滞。

文献信息

• TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3)
  申请人：ANCHORED RSK3 INHIBITORS, LLC

  公开号：US20140286928A1

  公开（公告）日：2014-09-25

  The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAPβ binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

  本发明提供了一种保护心脏免受损害的方法，通过向存在潜在损害风险的患者投放一种药效有效量的组合物，该组合物抑制RSK3和mAKAPβ之间的相互作用，或者抑制这两种分子中的一种或两种的表达或活性。该组合物可以是一种特异性抑制mAKAPβ与RSK3结合的肽形式，也可以是一种抑制RSK3表达的siRNA构建物形式。
• Synthesis of Inhibitors of P90Rsk
  申请人：Hecht Sidney M.

  公开号：US20080269144A1

  公开（公告）日：2008-10-30

  The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural SLO1O1-1 product and has provided access to material sufficient for detailed biological evaluation.

  自然存在的山柰酚苷SLO1O1-1及其类似物的合成已经完成，并对其进行了生化评估。SLO1O1-1在纳摩尔浓度下表现出选择性和强效的p90 Rsk抑制活性，而不抑制MEK、Raf或PKC等上游激酶的功能。本发明的合成方案验证了天然SLO1O1-1产物的结构分配，并提供了足够详细的生物评估材料。
• Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
  申请人：Kapiloff Michael S.

  公开号：US10907153B2

  公开（公告）日：2021-02-02

  The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, or the expression or activity of one or both of those molecules. This composition is preferably in the form of an siRNA construct, more preferably an shRNA construct, which inhibits the expression of mAKAPβ.

  本发明提供了一种保护心脏免受损害的方法，即向有可能受到这种损害的患者施用药学上有效量的组合物，这种组合物能抑制 RSK3 和 mAKAPβ 的相互作用，或抑制其中一个或两个分子的表达或活性。这种组合物最好采用 siRNA 构建物的形式，更优选 shRNA 构建物，它能抑制 mAKAPβ 的表达。
• Compositions for treating heart disease by inhibiting the action of mAKAPβ
  申请人：Anchored RSK3 Inhibitors, LLC

  公开号：US11229679B2

  公开（公告）日：2022-01-25

  The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAPβ binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

  本发明提供了一种保护心脏免受损伤的方法，即向有可能受到这种损伤的患者施用药学有效量的组合物，这种组合物能抑制 RSK3 和 mAKAPβ 的相互作用，或抑制这两种分子中的一种或两种的表达或活性。这种组合物可以是特异性抑制 mAKAPβ 与 RSK3 结合的多肽形式，也可以是抑制 RSK3 表达的 siRNA 构建物形式。
• Rsk inhibitors and therapeutic uses thereof
  申请人：Smith A. Jeffrey

  公开号：US20070049539A1

  公开（公告）日：2007-03-01

  The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.